echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Up to 90 per cent reduction: Medtron, Abbott, Lepp.

    Up to 90 per cent reduction: Medtron, Abbott, Lepp.

    • Last Update: 2020-10-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On September 14th, Hainan Province's pharmaceutical centralized procurement service platform issued the "Notice on the announcement of the results of the three provinces and cities in the joint belt procurement of crown balloons", announced Guizhou Province, Chongqing City, Hainan Province, three provinces and cities of the joint centralized bag procurement of selected enterprise results.
    the pre-expansion group crown expansion balloon selected enterprises include Hunan Epte, Shanghai Micro-Invasive, Jiwei Medical, Poco, Lepu, Medtron.
    expansion group after the expansion of the crown bag selected enterprises include Hunan Epte, Sano Medical, Shanghai Minimally Invas, Poco, Lepu, Abbott.
    According to people's network news, the volume of procurement pre-expansion group produced a total of 6 enterprises to be selected, 6 products to be selected, an average decline of 85.49%, the highest decline of 89.84%;
    85.32 percent overall, and is expected to save 190 million yuan in health insurance funds for the three provinces and cities.
    September 3, Guizhou Province pharmaceutical centralized procurement platform issued "on the publication of the crown pulse balloon centralized procurement enterprise audit results and enterprise representative products notice", announced the lowest price of enterprises hanging online.
    According to Seber Blue Equipment's previous estimate, the overall winning bid price may be between 200 yuan and 500 yuan, with reference to the average decline of 85.49 percent and the highest decline of 89.84 percent in the pre-expansion group, and the average decrease of 85.51 percent and the highest drop of 90.35 percent in the post-expansion group, the overall winning bid price may be between 250 yuan and 500 yuan.
    There is intervention without implantation it is understood that the coronary expansion balloon on the one hand is to cooperate with the stent to treat patients, on the other hand, recently there are industry insiders on the Cypress blue device said that there is intervention without implantation is becoming the development trend of coronary intervention field.
    China Industrial Information Network analysis, PCI has become the main means of coronary heart disease treatment, and with the increase in the number of stent use, intrast bracket stenosis (ISR) problem is becoming more serious, and the current ISR treatment program, coronary bypass transplant risk factors and more taboos, re-placed stent (stent stent) may trigger the risk of re-ISR and other multiple stents placed.
    drug-coated balloon (DrugCoated Ballon, DCB) is a new interventional treatment technology that has been used in China.
    It is understood that DCB consists of three parts: balloon, anti-proliferation drug and envelope carrier substance, which is transferred to the vascular wall quickly and evenly through the pro-lipid substrate during the single air bag inflating process without the use of permanent implants.
    according to the analysis of China Industrial Information Network, dcB has the following advantages compared with drug ealing stent (DES): (1) avoids the overlapping of 2 or even 3 layer brackets, and reduces the effect on coronary anatomy; (2) DCB can apply the drug evenly to the vascular wall, which can reduce the endotrification delay caused by the uneven distribution of stent metal rods; (3) does not require multiple polymers and does not induce late thrombosis; (4) may reduce the treatment time of double antiplate plate plate.
    DCB is an alternative method for DES treatment difficulties such as small blood vessels, anatomically curved blood vessels, diffuse long lesions, fork lesions, and mouth lesions.
    But the DCV generation can not completely replace THES, there are still some shortcomings: (1) can not solve the acute period elastic retractation of blood vessels, the balloon dilation of the severe mezzanine, affecting blood flow or acute vascular ococcysts, at this time still need to be placed in the stent; (2) DES is indeed better than DVC in the maximum tube cavity diameter after being placed, (3) coupled with continuous updating, the efficacy and safety of new products continue to improve, the long-term efficacy may be better than DBC, especially the target lesions blood transport reconstruction rate.
    According to the China Circulation Journal, recently released randomized controlled trial data show that the drug-coated balloon new technology combined with functional testing, the use of anti-proliferation drugs (inhibiting endometrial proliferation) and the shortening of the dual anti-course, and other advantages, may become an effective choice for the treatment of coronary heart disease in many clinical cases.
    Currently in China has armed enterprises began to lay out intervention without implantation, such as Lepu Medical's core innovative products bio-absorbable stent NeoVas stent system in February 2019 officially approved by the NMPA registration, marking its PCI technology into the "intervention without implantation" era.
    In addition, Lepu Medical "involvement without implantation" of a number of core products are in the process of research and development registration work - yew alcohol drug balloon (crown vein) in June 2019 by the NMPA registration application, in July through the first GMP audit, is expected to obtain registration approval in 2020;
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.